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ABSTRACT
Objective: The objective of this study is to estimate the effect of Vitamin D3 supplementation on endogenous Vitamin D3 level and inflammatory 
biomarkers in newly diagnosed pediatric patients.
Methods: The patients were given oral Vitamin D3, and they divided into three groups: The first group (25 healthy pediatrics), the second group (25 
newly diagnosed pediatric patients) treated with daily insulin regimen only, and the third group (25 newly diagnosed pediatric patients) treated with 
Vitamin D3 (2000 IU/day) with daily insulin regimen; all patients were treated for 90 days; and blood samples were taken at baseline and after 45 days 
and 90 days of starting Vitamin D3 to assess its potential effect on the levels of Vitamin D, serum calcium, serum alkaline phosphatase levels, and other 
inflammatory markers.
Results: The results of the current study showed that serum IL-1β significantly declined in patients receiving Vitamin D3, while serum Vitamin D3, 
serum calcium, and interleukins-4 were significantly increased in patients receiving Vitamin D3.
Conclusion: Daily vitamin D3 in addition to insulin offers favourable immunological effect in paediatric patients with Type I DM.
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INTRODUCTION
Diabetes mellitus (DM) is a persistent hyperglycemia caused by 
defects in insulin secretion, insulin action, or both [1]. Vitamin D, 
known primarily as a hormone of bone metabolism, can affect the 
transcription of a number of genes. In addition, Vitamin D may 
inhibit the renin–angiotensin system, reduce parathyroid hormone 
levels, decrease coagulation, reduce inflammation thereby reducing 
atherosclerosis, and increase insulin production [2], and other study 
found an association with asthma [3]. This persistent hyperglycemia 
may lead to long-term damage and loss of functions of many organs [4]. 
Symptoms of hyperglycemia include polyuria, polydipsia, polyphagia, 
blurred vision, and decrease in weight and to less common are 
insufficient growth and increase exposure to infections [1,5]. Type 1 
DM (T1DM) accounts for 5–10% of all cases of diabetes [6]. Genetic, 
environmental, and immunologic factors can cause the destruction of 
the pancreatic β-cells and insulin deficiency in T1DM, and mostly, this 
process results from autoimmune β-cell destruction, although not all 
cases have the evidence of islet directed autoimmunity [7].
Individuals with a genetic susceptibility have normal β-cell mass at birth 
but start to lose their β-cells secondary to the autoimmune destruction 
that may occur over months to years, and this autoimmune process 
is thought to be triggered effect and continuously progress through a 
β-cell-specific molecule. The disease becomes clinically clear after the 
development of immunologic markers in the presence of the stimulating 
event. After that, β-cell mass begins to decline or about 80% of β-cells 
are destroyed, and insulin secretion becomes gradually impaired, but 
the glucose tolerance remained normal [8]. In vitro study suggested 
that interleukin-1 (IL-1) and tumor necrosis factor, two cytokines 
mostly produced by macrophages, induce structural changes of β-cells 
and suppression of their insulin releasing ability [9]. The children were 
given 2000 IU of Vitamin D daily in early childhood associated with 
reduced risk of T1DM. However, the mechanism stilled unclear [10,11]. 
Studies on a systemic defect in immune regulation suggested that 
natural killer T-cells (NKTC) activity and antigen presenting cells (APC) 
function are all decreased in diabetic patients [12]. On the other hand, 
lack of NKTC activity also results in the fewer amount of IL-4 production 
and subsequently lower amount of APC activation than required to 
maintain the normal immunity functions [13]. Vitamin D3 influences the 
pathogenesis, risks, and complications of DM. Studies have shown that 
Vitamin D3 supplementation in infancy reduces the risk of developing 
T1DM later in early adulthood [14]. Vitamin D3 receptors have immune-
modulating effects, and the development of T1DM may be associated 
with polymorphisms in the Vitamin D receptor gene [15,16].
METHODS
This is a prospective randomized controlled open-label study carried 
out in Child Central Teaching Hospital in the outpatient clinic of the 
endocrinology department during the period from April 2015 to May 
2016. The study was approved by the Ethics Committee by College 
of Pharmacy/University of Al-Mustansiriyah, and written informed 
consent was taken from all participants (their legal guardian since all 
of them are minors). The study was conducted on 50 newly diagnosed 
T1DM patients (with duration of disease ≤1 year), and ages were 
between 4 and 12 years. The patients’ records were kept for the next 
3 months after their initial visit to the hospital; they were observed 
for Vitamin D3 that measured before and after 45 days and after 
90 days of treatment. All the patients kept on similar management 
and dose of Vitamin D3, as well as their regular medications for 
DM. The patients were randomized into two groups: Group 1 with 
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25 patients receive 2000 IU Vitamin D3 once daily only in addition to the 
normal insulin regimen and Group 2 with 25 patients receive insulin 
(soluble and lente) twice daily.
From all eligible subjects, demographic (age and gender) and laboratory 
markers (Vitamin D, ionized calcium, alkaline phosphatase [ALP], 
IL1β, and IL4) were recorded at baseline and after 45 and 90 days for 
both the groups.
About 5 ml of fasting venous blood collected and serum stored at −20°C 
after separation, and this sample was used to assess the serum levels 
of fetal bovine serum, hemoglobinAlc, ionized calcium, ALP, Vitamin D, 
IL-1β, and IL-4, as illustrated in Table 1.
Statistical analysis
Data were presented in simple measures of frequency, mean, and 
standard error. The significance of the difference of different means 
(quantitative data) was tested using students’ t-test for the difference 
between two independent means or paired t-test for difference of 
paired observations (or two dependent means). The significance of 
the difference of different percentages (qualitative data) was tested 
using Pearson Chi-square test with application of Yate’s correction 
or Fisher’s exact test whenever applicable. SPSS version 20 
(USA, Chicago, IL) software package was used for the statistical 
analysis. Statistical significance was considered whenever the 
P value was ≤.05.
RESULTS
There was no significant difference in age and gender between Groups 1 
and 2, as illustrated in Table 2.
Serum Vitamin D3 was significantly higher in Group 1 compared to 
Group 2 after 45 and 90 days, and in Group 1, serum Vitamin D3 increased 
from 45 to 90 days, but it was not statistically significant, while for 
Group 2, there was a significant reduction in serum Vitamin D3 from 
45 days to 90 days. In Group 1, serum IL1β significantly reduced after 
90 days, while no significant change in Group 2 was observed. In 
Group 1, serum IL4 was significantly increased after 90 days, while 
in Group 2, there was a significant reduction in IL4 after 90 days, as 
illustrated in Table 3.
There was no significant association between Vitamin D with 
inflammatory markers after supplementation of Vitamin D, as 
illustrated in Table 4.
DISCUSSION
In the current study serum, IL1β was significantly decreased in patients 
receiving Vitamin D3 in addition to insulin while those who did not 
receive Vitamin D3 had a non-significant increase in IL1β, and also, 
serum IL4 was significantly increased after 90 days for those receiving 
Vitamin D3 while those receiving insulin only had a significant decrease 
in IL4 serum levels.
It is understandable now that Vitamin D displays an anti-inflammatory 
effect as one of its major roles, and its deficiency is often accompanied 
with increased risk of any inflammatory, immunological, and 
autoimmune disorders. The active biological metabolite of Vitamin D 
[Vitamin D3] is a potent regulator of the immune response and functions 
by binding to the Vitamin D receptor with immunomodulatory 
properties [17].
Contact et al. study shows an inhibitory effect for Vitamin D3 on Th1 
cell activation where these cells play an essential part in immune 
and inflammatory diseases by producing inflammatory cytokines, 
such as IL-1, and thus, Vitamin D3 plays an important key role in the 
inhibition, differentiation, and proliferation of both T and B cells, 
reduces polarity of Th0 cells to Th1 cells, and inhibits the generation and 
production of cytokines which leads to destruction of pancreatic islet 
cells and then induces endoplasmic reticulum stress and apoptosis by 
pro-inflammatory cytokine [18-20]. Furthermore, these cells produce 
Vitamin D3 which then regulates their proliferation and function [21].
Our findings were in agreement with Cantorna et al. study that 
production of the Th2-associated cytokine IL-4 could be upregulated by 
Table 1: List of various laboratory markers used in the study 
with its supplier
Suppliers Diagnostic kit
RANDOX, UK Fasting blood glucose kit (manual), 
ELISA
Cobas 411 (ROCH), Germany Insulin kit (auto-analyzer)
RANDOX, UK Ca kit, ELISA
bioMerieux, France ALP kit, ELISA
bioMerieux, France Vitamin D3 kit, auto-analyzer
Bio-Rad, USA HbA1c kit auto-analyzer
Elabscience, China IL 1β kit, ELISA
Elabscience, China- IL 4 kit, ELISA
ALP: Alkaline phosphatase, IL: Interleukin
Table 2: Demographic data of the patients
Variables T1DM and Vitamin D T1DM p-value
Age (years) 8.2±2.5 8.8±2.6 0.410
Gender
Female 17 (68%) 13 (52%) 0.248
Male 8 (32%) 12 (48%)
Data presented as mean±SD, T1DM: Type 1 diabetes mellitus
Table 3: Assessment of various markers in pediatric patients 
with T1DM




Baseline 11.05±0.992a 15.0±1.565a 0.038
After 45 days 18.55±1.081b 14.14±1.051a 0.009
After 90 days 26.41±1.796b 10.52±0.808b <0.001
Calcium ionized (mmol/L)
Baseline 1.56±0.089a 1.76±0.093a 0.127
After 45 days 1.54±0.079a 1.65±0.078b 0.327
After 90 days 1.74±0.089b 1.50±0.076b 0.046
ALP (U/L)
Baseline 291.2±26.613 333.81±18.591 0.196
After 45 days 293.12±21.905 327.82±20.429 0.252
After 90 days 306.80±20.027 351.66±17.280 0.096
IL1β (pg/ml)
Baseline 9.435±2.54a 6.587±2.205a 0.401
After 90 days 3.017±0.452b 11.731±4.316a 0.049
IL4 (pg/ml)
Baseline 36.546±24.064a 55.889±19.728a 0.537
After 90 days 47.297±27.430b 13.832±2.919b 0.231
Data were presented as mean±SEM similar letters within a columns  
(a, b, and c) denote no significant difference between means; otherwise, they 
differ significantly (p<0.05), IL1β: Interleukin1β, IL4: Interleukin4, ALP: Alkaline 
phosphatase, T1DM: Type 1 diabetes mellitus, SEM: Standard error of the mean
Table 4: Association between vitamin D with inflammatory 
markers at baseline and after supplementation of vitamin D
Markers Serum vitamin D
Baseline After 90 days
r p-value r p-value
IL1β −0.198 0.343 −0.165 0.431
IL4 −0.017 0.936 0.022 0.919
r: Correlation coefficient, IL1β: Interleukin1β, IL4: Interleukin4
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Vitamin D3 treatment [22], also Vitamin D3 inhibited Th1 cell expansion 
and cytokine production and resulted in Th2 cell expansion and increased 
IL-4 production [22,23] with promoting the Th2 cytokine production of 
IL-4, for that reason orientated T cell response towards Th2 dominance 
thus it increase the production of more anti-inflammatory Th2 cytokines 
(IL3, IL4, IL5, IL10)  and inhibits Th1 response activity seems to play a 
major role in the treatment of autoimmune diseases [24]. The present 
study compatible with Virtanen et al. studies showed that Vitamin D3 
administration had been shown to increase IL-4 and improve Vitamin D3 
that may make the clear deviation in the immune system, specifically 
in THC [25]. The role of regulation IL-4 production is controversial 
as Gregori et al. showed that the inhibition of both Th1 and Th2 cell 
cytokine production, including the inhibition of IL-4 [which then may 
trigger humoral immunity leads to antibody production] [26].
CONCLUSION
Daily vitamin D3 in addition to insulin offers favourable immunological 
effect in paediatric patients with Type I DM.
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